Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.959 +0.229 (+3.41%)
Streaming Delayed Price Updated: 3:16 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
WeTrade's Monkeypox Testing Kits May Go Global. Why A New Agreement Is Sending Shares Soaring Double Digits?
Via Benzinga
FDA Issues Warning Letter For Emergent Bio's Manufacturing Facility
Via Benzinga
Emergent BioSolutions Posts Q2 Loss On Lower Sales, Q3 Forecasts Below Consensus
Via Benzinga
Avis Budget, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
  FAT Brands Inc. (NASDAQ: FATBB) fell 30% to $10.50. The company recently posted a Q2 net loss of $8.2 million or $0.50 per share. 
Via Benzinga
Merck Partner Joins Forces With Emergent Bio To Increase Access To Ebola Treatment
Via Benzinga
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese stocks. 
Via Benzinga
Why Applied DNA Sciences Is Trading Higher By 166%, Here Are 75 Stocks Moving In Tuesday's Mid-Day Session
Gainers AMTD IDEA Group (NYSE: AMTD) shares jumped 284% to $8.00 after jumping 18% on Monday. The company owns 90%+ of AMTD Digital. 
Via Benzinga
Recap: Emergent BioSolutions Q2 Earnings
Emergent BioSolutions (NYSE:EBS) reported its Q2 earnings results on Monday, August 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears
Monkeypox stocks are rallying today amid worries about a shortage of vaccines for the illness in the United States. 
Via InvestorPlace
Earnings Outlook For Emergent BioSolutions
Emergent BioSolutions (NYSE:EBS) is set to give its latest quarterly earnings report on Monday, 2022-08-01. Here's what investors need to know before the announcement. Analysts estimate that Emergent... 
Via Benzinga
Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency
Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections. 
Via InvestorPlace
WWE, Infrastructure and Energy Alternatives And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
  Infrastructure and Energy Alternatives, Inc. (NASDAQ: IEA) shares rose 26% to $13.14 in pre-market trading. MasTec announced plans to acquire Infrastructure and Energy Alternatives for $14 per share... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For August 1, 2022
Companies Reporting Before The Bell • Bon Natural Life (NASDAQ:BON) is projected to report earnings for its first quarter. 
Via Benzinga
Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile
Pharmaceutical companies that make vaccines against monkeypox are getting attention as demand for treatments against the virus grow. 
Via InvestorPlace
White House Outlines New Monkeypox Vaccine Strategy: What You Need To Know
Via Benzinga
U.S. FDA Accepts Emergent's Anthrax Vaccine Candidate Filing For Review
The U.S. Food and Drug Administration (FDA) has accepted to review Emergent BioSolutions’ (NYSE: EBS) Biologics License Application (BLA) for its new anthrax vaccine candidate AV7909. The regulatory... 
Via Benzinga
7 Penny Stocks That Could Triple in 2022
Penny stocks are affordable and some with credible business models in all likelihood have the potential to generate superior returns. 
Via InvestorPlace
7 No-Brainer Biotech Stocks to Add to Your Buy List
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. 
Via InvestorPlace
7 Monkeypox Stocks That May Take Off in Q2
SIGA Technologies (SIGA) may lead on the list of Monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. 
Via InvestorPlace
Morning Brief: Top Financial Stories Dominating on Tuesday, June 7
Reuters 
Via Benzinga
J&J Serves Notice To Emergent For Terminating COVID-19 Shot Contract As Two Accuse Each Other Of Breach Of Agreement
Johnson & Johnson (NYSE: JNJ) has made another move towards severing its Covid-19 vaccine manufacturing ties with contract manufacturer Emergent Biosolutions, Inc. (NYSE: EBS). 
Via Benzinga
Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract
Emergent BioSolutions Inc (NYSE: EBS) said Johnson & Johnson (NYSE: JNJ) had breached an agreement by failing to buy the company's minimum quantity of COVID-19 vaccines. 
Via Benzinga
Monkeypox Outbreak Puts Focus On These Two Biotechs
Just when you thought it was safe to go outside, monkeypox pops up. Still, this might not be bad news for the market, as the world will turn once again to vaccine makers to find a solution. 
Via Talk Markets
7 Monkeypox Stocks to Watch Right Now
Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus. 
Via InvestorPlace
Morning Brief: Top Financial Stories Dominating on Tuesday, May 24
CNBC 
Via Benzinga
WHO Says Monkeypox Outbreak 'Unusual' But 'Containable'
The World Health Organization (WHO) said that there had been 131 confirmed monkeypox cases and 106 further suspected cases, 
Via Benzinga
Why Emergent Biosolutions Stock Is Rising Today
Emergent Biosolutions Inc (NYSE: EBS) shares are trading higher Monday amid increasing monkeypox concerns. 
Via Benzinga
24 Stocks Moving in Monday's Pre-Market Session
Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday. 
Via Benzinga
6 Stocks To Watch Amid Monkeypox Outbreak
A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.